Physician profile
John Robert Pradko
NPI 1619956497
$5,603.08
in general payments reported to CMS, 2019-2025
36 companies · $32.37 in 2025
The $32.37 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $886 · 2021: $1,001 · 2022: $708 · 2023: $1,327 · 2024: $610 · 2025: $32.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,192.78 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $949.34 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Pfizer INC. | $567.64 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.52 | 2019-2024 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Amgen INC. | $400.56 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $279.42 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $265.34 | 2019-2024 | Breztri, Flumist Quadrivalent, Airsupra |
| Novartis Pharmaceuticals Corporation | $176.84 | 2019-2024 | |
| Abbvie INC. | $156.00 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.98 | 2019-2022 | |
| Amarin Pharma, INC. | $110.79 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.93 | 2021-2024 | |
| Astellas Pharma US INC | $101.17 | 2019-2023 | Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $81.06 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.05 | 2019-2023 | Eliquis |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pradko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.